Atlas FDA

Predicate Research Report · generated 2026-08-22 · Print / save as PDF · Save to account

Alamar — Predicate Candidate Screening

7 FDA 510(k) clearances under this manufacturer; the 50 most recent screened below.

40 daysmedian FDA review time
40 days90th percentile
7clearances measured
K-numberDeviceApplicantDecidedReview daysRecalls (K-match)
K911392ANTIMICROBIAL SUSCEPTIBILITY TEST PANEL (CEFOTETANAlamar1991-05-08400
K911391ANTIMICROBIAL SUSCEPT. TEST PANEL (CEFTIZOXIME)Alamar1991-05-08400
K911390ANTIMICROBIAL SUSCEPT. TEST PANEL(TRIMETHOPRIM)Alamar1991-05-08400
K911389ANTIMICROBIAL SUSCEPTIBILITY TEST PANEL (IMIPENEM)Alamar1991-05-08400
K910484ANTIMICROBIAL SUSCEPTIBILITY TEST PANELAlamar1991-03-11330
K910345ANTIMICROBIAL CEFOPERAZONEAlamar1991-02-25280
K910346ANTIMICROBIAL CEFTRIAXONEAlamar1991-02-25280

Methodology

Recall counts reflect FDA recall records explicitly referencing each K-number; FDA links recalls to K-numbers inconsistently, so 0 means "none found in FDA records," not "never recalled." Data: FDA openFDA, refreshed weekly. Verify decisions of consequence against the primary source. Full candidate set and CSV export: atlasbyauro.com.

Prepared with Atlas

Predicate research, review-time statistics and recall monitoring for 510(k) teams — atlasbyauro.com/fda